Literature DB >> 12352046

Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells.

Georg Hoffmann1, Monika Czechowski, Michaela Schloesser, Wolfgang Schobersberger.   

Abstract

OBJECTIVE: Elevated procalcitonin concentrations are found in the course of systemic inflammation caused by bacterial insults, for example, sepsis and septic shock. However, the source of procalcitonin and its role in the inflammatory process are still unknown. In clinical studies, procalcitonin concentrations reflected the severity of sepsis and were predictive of mortality, suggesting that an increased procalcitonin synthesis is detrimental for the host. In contrast, and data report anti-inflammatory effects of procalcitonin that rather may represent a benefit for the septic patient.
DESIGN: Prospective, controlled, cell culture study.
SETTING: University research laboratories.
SUBJECTS: WKY rats.
INTERVENTIONS: We investigated whether procalcitonin affects one principal mediator of sepsis, inducible nitric oxide synthase-derived nitric oxide, taking into account the typical 3-hr delay of procalcitonin increase following a bacterial challenge. Vascular smooth muscle cells were incubated with lipopolysaccharide (10 microg/mL), tumor necrosis factor-alpha (500 units/mL), interferon-gamma (100 units/mL), and procalcitonin (1, 10, 100, and 1000 ng/mL). Cells were preincubated with lipopolysaccharide for 90 mins followed by the addition of tumor necrosis factor-alpha/interferon-gamma. In a second set of experiments, procalcitonin was added to these proinflammatory agonists 3 hrs after lipopolysaccharide application.
MEASUREMENTS AND MAIN RESULTS: Although no inducible nitric oxide synthase complementary DNA was detectable in unstimulated controls and following single application of procalcitonin, inducible nitric oxide synthase gene expression was induced in cells treated with lipopolysaccharide plus tumor necrosis factor-alpha/interferon-gamma for a total incubation time of 24 hrs. When vascular smooth muscle cells were incubated with procalcitonin in addition to lipopolysaccharide plus tumor necrosis factor-alpha/interferon-gamma, a further stimulation of inducible nitric oxide synthase transcription rate could be detected.
CONCLUSIONS: These results provide evidence that procalcitonin acts as a modulator that augments the inflammatory response triggered by agonists like lipopolysaccharide, tumor necrosis factor-alpha, and interferon-gamma. Although not effective as a single stimulus, it might contribute to the detrimental outcome following excessive activation of the inflammatory cascade.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352046     DOI: 10.1097/00003246-200209000-00023

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

Review 1.  Immune regulation of procalcitonin: a biomarker and mediator of infection.

Authors:  G N Matwiyoff; J D Prahl; R J Miller; J J Carmichael; D E Amundson; G Seda; M Daheshia
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

Review 2.  Adipocyte, adipose tissue, and infectious disease.

Authors:  Mahalia S Desruisseaux; Maria E Trujillo; Herbert B Tanowitz; Philipp E Scherer
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 3.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

Review 4.  Overview of procalcitonin in pregnancy and in pre-eclampsia.

Authors:  A Mangogna; C Agostinis; G Ricci; F Romano; R Bulla
Journal:  Clin Exp Immunol       Date:  2019-06-13       Impact factor: 4.330

5.  Serum value of procalcitonin as a marker of intestinal damages: type, extension, and prognosis.

Authors:  C Cosse; C Sabbagh; F Browet; F Mauvais; L Rebibo; E Zogheib; D Chatelain; S Kamel; J M Regimbeau
Journal:  Surg Endosc       Date:  2015-02-21       Impact factor: 4.584

6.  Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils.

Authors:  Guillaume Monneret; Maud Arpin; Fabienne Venet; Karim Maghni; Anne-Lise Debard; Alexandre Pachot; Alain Lepape; Jacques Bienvenu
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

7.  Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients.

Authors:  Markéta Marková; Helena Brodská; Karin Malíčková; Veronika Válková; Petr Cetkovský; Michal Kolář; Martin Haluzík
Journal:  Support Care Cancer       Date:  2013-05-28       Impact factor: 3.603

8.  Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia.

Authors:  Nicolas Boussekey; Olivier Leroy; Serge Alfandari; Patrick Devos; Hugues Georges; Benoit Guery
Journal:  Intensive Care Med       Date:  2006-02-14       Impact factor: 17.440

9.  Year in review: Critical Care 2004 - nephrology.

Authors:  Zaccaria Ricci; Claudio Ronco
Journal:  Crit Care       Date:  2005-08-19       Impact factor: 9.097

10.  Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients.

Authors:  Michael Meisner; Heide Adina; Joachim Schmidt
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.